Despite decades of dedicated research, there remains a dire need for new drugs against
tuberculosis (TB). Current therapies are generations old and problematic. Resistance to …

Coenzyme A (CoA) is an essential cofactor involved in a range of metabolic pathways
including the activation of long‐chain fatty acids for catabolism. Cells synthesize CoA de …

Allostery is an important regulatory mechanism of protein functions. Among allosteric
proteins, certain protein structure types are more observed. However, how allosteric …

The pantothenate analogue hopantenate (HoPan) is widely used as a modulator of
coenzyme A (CoA) levels in cell biology and disease models─ especially for pantothenate …

Cholesterol is a critical growth substrate for Mycobacterium tuberculosis (Mtb) during
infection, and the cholesterol catabolic pathway has been targeted for the development of …

Currently, allosteric inhibitors have emerged as an effective strategy in the development of
preservatives against the drug-resistant Botrytis cinerea (B. cinerea). However, their …

Tuberculosis (TB) is the foremost cause of infectious fatality globally. The primary global
challenge in combatting TB lies in addressing the emergence of drug-resistant variants of …

New drugs and new targets are urgently needed to treat tuberculosis. We discovered that d-
phenylalanine-benzoxazole Q112 displays potent antibacterial activity against …

Background Schistosomiasis is the world's second most devastating disease after malaria
and the leading cause of disease and mortality for more than 200 million people in …

Coenzyme A (CoA) is a ubiquitous cofactor present in all living cells and estimated to be
required for up to 9% of intracellular enzymatic reactions. Mycobacterium tuberculosis (Mtb) …